SCIENTIFIC RATIONALE
The course will provide a comprehensive update on the treatment of thoracic malignancies with special emphasis on the multimodality treatment. To that regard there is a wide participation of thoracic surgeons, chest physicians and oncologists.
At the end of the course participants will be able to:
- have a deeper knowledge of diagnostic modalities for thoracic malignancies
- be familiar with the most up to date form of treatment according to stage
- be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages
- be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).

SCIENTIFIC DIRECTOR
Dr. Federico Raveglia

SCIENTIFIC BOARD
Paolo Bidoli
Alessandro Brunelli
Diego Cortinovis
Thomas D’Amico
Marialuisa Lavitrano
Gaetano Rocco
Marco Scarci

FACULTY
Stefano Arcangeli
Hasan Batirel
Ignacio Gil-Bazo
Alex Brunelli
Federico Cappuzzo
Giuseppe Cardillo
Diego Cortinovis
Roberto Crisci
Tommy D’Amico
Massimo Del Torre
Pierre Emmanuel Falcoz
Mahmoud Ismail
Kevin Lau
Gilbert Massard
Neal Navani
Mario Nosotti
Nuria Novoa
Kostas Papagiannopoulos
Alexander Patterson
Nir Peled
Jordi Remon
SCIENTIFIC PROGRAMME

NOVEMBER 6TH 2020

8:30-8:45 Registration

8:45-09:00 Introduction

I SESSION

How do we diagnose lung cancer?
Chair: A. Brunelli, M. Del Torre

09:00-09:20 Nelson study: what have we learnt and what is left to do? T. D’amico

09:20-09:40 Alternatives to CT screening: are they viable? G. Massard

09:40-10:00 New bronchoscopic techniques: friend or foe? N. Navani

10:00-10:20 Radiologic diagnosis of lung cancer: when is it enough? A. Patterson

10:20-10:40 Intraoperative radiologic biopsy: does the cost justify the result? K. Papagiannopoulos

10:40-11:00 Questions

11:00-11:30 Coffee Break

II SESSION

How to approach lung cancer
Chair: G. Cardillo, K. Papagiannopoulos

11:30-11:50 GGOs and subsolid lesions: classification and natural history N. Novoa

11:50-12:10 Resection vs surveillance for GGOs N. Navani

12:10-12:30 Surgery vs SBRT for operable patients: is there a role? S. Arcangeli
12:30-12:50  Surgery vs radiofrequency ablation  
* M. Scarci *

12:50-13:10  Surgery vs ENB navigation ablation  
* K. Lau *

13:10-13:30  Questions

13:30-14:30  Lunch

**III SESSION**

**Preoperative management**

Chair: *T. D'Amico, P. Solli*

14:30-14:50  Do we need to stage the mediastinum?  
* E. Ruffini *

14:50-15:10  Do we need to biopsy a lesion before surgery?  
* M. Ismail *

15:10-15:30  Neoadjuvant treatments for early stage lung cancer: is there a role?  
* D. Cortinovis *

15:30-15:50  Where do we draw the line for indications for surgery? The truly inoperable patient  
* A. Brunelli *

15:50-16:10  Questions

16:10-16:40  Coffee Break

**III SESSION**

**How to treat early stage lung cancer**

Chair: *R. Crisci, G. Massard*

16:40-17:00  Robotic surgery  
* D. G. Rivas *

17:00-17:20  Minimally invasive approaches  
* D. G. Rivas *

17:20-17:40  Hybrid techniques  
* P. M. Falcoz *

17:40-18:00  How much can we push minimally invasive surgery?  
* H. Batirel *

18:00-18:20  Questions and Closing Remarks

18:20  End of day 1
NOVEMBER 7th 2020

8:00-8:30 Registration

IV SESSION
Medical treatments
Chair: S. Arcangeli, N. Navani, J. Remon

08:30-08:50 Immunotherapy in resectable NSCLC
Y. Summers

08:50-09:10 News in immunotherapy world in advanced NSCLC: improving the bar
N. Peled

09:10-09:30 Neoadjuvant strategies in oncogene addicted tumors: is it now the time?
I. Gil-Bazo

09:30-09:50 Oncogene addicted tumors: new OMA’s to know
C. Rolfo

09:50-10:10 SCLC a new dawn or the same old refrain
D. Cortinovis

10:10-10:30 Questions

10:30-11:00 Coffee Break

V SESSION
Multimodality treatments
Chair: M. Nosotti, A. Patterson

11:00-11:30 Concomitant neoadjuvant chemoRT vs neoadjuvant chemo vs surgery upfront
T. D’amico

11:30-12:00 Treatment of (un)resectable stage III lung cancer
F. Cappuzzo

12:00-12:30 Oligometastatic disease: when is too much for surgery?
G. Rocco

12:30-13:00 Multimodality approach for orphan diseases: MPM and SCLC
J. Remon

13:00-13:30 CME Tests

13:30 Symposium End

13:30-14:30 Lunch
GENERAL INFORMATIONS
Milan, 6th – 7th November 2020
FONDAZIONE STELLINE
Corso Magenta, 61
20123 MILANO

Provider ECM – Ethical Medtech and Organising Secretariat

MICOM S.r.l. – Provider ID 758 -
Via B. Verro, 12 - 20141 Milano (Italy)
Tel. +39 02 89518895 - Fax +39 02 89518954
E-mail: micom@micom.it - Sito Internet: www.micom.it